ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires
ViaDerma, Inc. (OTC Pink: VDRM) has announced significant developments in its global expansion strategy. The company has finalized distribution agreements with two leading companies in Dubai, aimed at expanding the availability of its flagship topical antibiotic product, Vitastem, in the Middle East and Eastern Europe. To support this growth, ViaDerma has made six key hires, including a Business Development Analyst, Project Manager, HR Specialist, Fractional COO, and a Regulatory Specialist with FDA experience. A new Chief Technology Officer is also set to join soon.
Dr. Christopher Otiko, President of ViaDerma, expressed optimism about the company's future growth prospects and hinted at a forthcoming announcement regarding a large international shipment of Vitastem. These strategic moves position ViaDerma for significant expansion beyond the United States market.
ViaDerma, Inc. (OTC Pink: VDRM) ha annunciato sviluppi significativi nella sua strategia di espansione globale. L'azienda ha finalizzato accordi di distribuzione con due importanti aziende a Dubai, con l'obiettivo di ampliare la disponibilità del suo prodotto antibiotico topico di punta, Vitastem, in Medio Oriente e nell'Europa orientale. Per supportare questa crescita, ViaDerma ha effettuato sei assunzioni chiave, tra cui un Analista di Sviluppo Commerciale, un Project Manager, uno Specialista HR, un COO frazionale e uno Specialista Regolatorio con esperienza FDA. Un nuovo Chief Technology Officer si unirà presto al team.
Il Dr. Christopher Otiko, Presidente di ViaDerma, ha espresso ottimismo riguardo alle prospettive di crescita future dell'azienda e ha accennato a un annuncio imminente riguardante una grande spedizione internazionale di Vitastem. Queste mosse strategiche posizionano ViaDerma per un'espansione significativa al di là del mercato statunitense.
ViaDerma, Inc. (OTC Pink: VDRM) ha anunciado desarrollos significativos en su estrategia de expansión global. La compañía ha finalizado acuerdos de distribución con dos empresas líderes en Dubái, con el objetivo de ampliar la disponibilidad de su producto antibiótico tópico insignia, Vitastem, en Oriente Medio y Europa del Este. Para apoyar este crecimiento, ViaDerma ha realizado seis contrataciones clave, incluyendo un Analista de Desarrollo Comercial, un Gerente de Proyecto, un Especialista en Recursos Humanos, un COO fraccionario y un Especialista Regulatorio con experiencia en la FDA. También se espera que un nuevo Director de Tecnología se una pronto.
El Dr. Christopher Otiko, Presidente de ViaDerma, expresó optimismo sobre las perspectivas de crecimiento futuro de la empresa y sugirió un anuncio inminente sobre un gran envío internacional de Vitastem. Estos movimientos estratégicos posicionan a ViaDerma para una expansión significativa más allá del mercado estadounidense.
ViaDerma, Inc. (OTC Pink: VDRM)는 글로벌 확장 전략에서 중요한 발전을 발표했습니다. 회사는 중동과 동유럽에서 주요 항생제 제품인 Vitastem의 사용 가능성을 넓히기 위해 두 개의 선도적인 기업과 배급 계약을 체결했습니다. 이 성장을 지원하기 위해 ViaDerma는 6개의 핵심 인력을 채용했습니다, 여기에는 비즈니스 개발 분석가, 프로젝트 관리자, 인사 전문, 분기별 COO 및 FDA 경험이 있는 규제 전문가가 포함됩니다. 새로운 최고 기술 책임자도 곧 합류할 예정입니다.
ViaDerma의 사장인 Christopher Otiko 박사는 회사의 미래 성장 전망에 대한 낙관적인 반응을 보였으며, Vitastem의 대규모 국제 선적에 대한 곧 발표될 소식에 대해 암시했습니다. 이러한 전략적 조치는 ViaDerma가 미국 시장을 넘어 중대한 확장을 할 수 있도록 자리매김합니다.
ViaDerma, Inc. (OTC Pink: VDRM) a annoncé des développements significatifs dans sa stratégie d'expansion mondiale. L'entreprise a finalisé des accords de distribution avec deux sociétés leaders à Dubaï, visant à élargir la disponibilité de son produit antibiotique topique phare, Vitastem, au Moyen-Orient et en Europe de l'Est. Pour soutenir cette croissance, ViaDerma a effectué six recrutements clés, dont un Analyste en Développement Commercial, un Chef de Projet, un Spécialiste en Ressources Humaines, un COO fractionnel et un Spécialiste en Réglementation avec une expérience à la FDA. Un nouveau Directeur Technique rejoindra également prochainement l'équipe.
Le Dr. Christopher Otiko, Président de ViaDerma, a exprimé son optimisme concernant les perspectives de croissance futures de l'entreprise et a fait allusion à une annonce prochaine concernant un important envoi international de Vitastem. Ces mouvements stratégiques positionnent ViaDerma pour une expansion significative au-delà du marché américain.
ViaDerma, Inc. (OTC Pink: VDRM) hat bedeutende Entwicklungen in seiner globalen Expansionsstrategie angekündigt. Das Unternehmen hat Vertriebsvereinbarungen abgeschlossen mit zwei führenden Unternehmen in Dubai, um die Verfügbarkeit seines Flaggschiff-Topikums Vitastem im Nahen Osten und in Osteuropa zu erweitern. Um dieses Wachstum zu unterstützen, hat ViaDerma sechs Schlüsselrekrutierungen vorgenommen, darunter einen Business Development Analysten, einen Projektmanager, einen HR-Spezialisten, einen fractional COO und einen Regulatory Specialist mit FDA-Erfahrung. Ein neuer Chief Technology Officer wird ebenfalls bald hinzukommen.
Dr. Christopher Otiko, Präsident von ViaDerma, äußerte Optimismus über die zukünftigen Wachstumsperspektiven des Unternehmens und deutete auf eine bevorstehende Ankündigung eines großen internationalen Vitastem-Versands hin. Diese strategischen Schritte positionieren ViaDerma für eine signifikante Expansion über den US-Markt hinaus.
- Finalized distribution agreements in Dubai to expand market presence in Middle East and Eastern Europe
- Added six new key hires to support global expansion efforts
- Upcoming announcement of a large new international shipment of Vitastem
- None.
LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), a leader in innovative wound care solutions, proudly announces the successful completion of pivotal distribution agreements across the Middle East and Eastern Europe. Dr. Christopher Otiko, President of ViaDerma, recently returned from the United Arab Emirates, where he met with representatives from two leading distribution companies in Dubai and finalized agreements centered around ViaDerma's flagship topical antibiotic product. These agreements are designed to significantly expand the company's global market presence. The partner companies, known for their expertise in supplying wholesale products to private enterprises and government entities, will play a crucial role in enhancing the availability of Vitastem in these strategically important regions. This collaboration marks a major step forward in ViaDerma's mission to provide advanced wound care solutions globally.
As a result of these important partnerships, ViaDerma has added six new key hires to help coordinate the global expansion efforts. A Business Development Analyst, a Project Manager, an HR Specialist, a Fractional COO, and a Regulatory Specialist with 16 years of FDA experience began their new roles on June 1st. The company is also set to welcome a new Chief Technology Officer next week, who will play a crucial role in advancing the company's technological capabilities. These strategic hires underscore ViaDerma's commitment to expanding its expertise and operational capacity, enabling it to better serve its future global customer base.
“We are very pleased to enter into these new partnerships at this time and to welcome these talented individuals to our team,” said Dr. Otiko. “There have been many challenges to reach this point, but we feel we have finally positioned ourselves for significant growth outside of the United States. I believe we have set the stage for an exciting future as we work towards expanding the availability of Vitastem and other products we hope to roll out in the future.”
Dr. Otiko also said, “We expect to make an announcement as early as next week with details of a large new international shipment of Vitastem.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter: https://twitter.com/viaderma
FAQ
What new distribution agreements has ViaDerma (VDRM) recently finalized?
How many new hires did ViaDerma (VDRM) announce in August 2024?
What is the main product ViaDerma (VDRM) is focusing on for international expansion?
When did the new hires at ViaDerma (VDRM) start their roles?
